| 更上一层楼——奥希替尼辅助治疗完全切除的EGFR基因突变阳性非小细胞肺癌患者：ADAURA |
| |
| 引用本文： | 齐一凡,钟文昭,张嘉涛. 更上一层楼——奥希替尼辅助治疗完全切除的EGFR基因突变阳性非小细胞肺癌患者：ADAURA[J]. 循证医学, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005 |
| |
| 作者姓名： | 齐一凡 钟文昭 张嘉涛 |
| |
| 作者单位： | 广东省人民医院肿瘤中心肺二科、 广东省医学科学院, 广东省肺癌研究所, 广州 510080 |
| |
| 摘 要： | 1文献来源Wu YL,Tsuboi M,He J,et al.Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J].N Engl J Med,2020,383(18):1711-1723.Wu YL,John T,Grohe C,et al.Postoperative chemotherapy use and outcomes from ADAURA:Osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC[J].J Thorac Oncol,2021,S1556-0864(21)03285-8.Online ahead of print.2证据水平1b。
|
| 关 键 词： | 表皮生长因子受体 非小细胞肺癌 辅助治疗 奥希替尼 |
The Next Level:ADAURA,Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer |
| |
| QI Yi-fan,ZHONG Wen-zhao,ZHANG Jia-tao. The Next Level:ADAURA,Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. The Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005 |
| |
| Authors: | QI Yi-fan ZHONG Wen-zhao ZHANG Jia-tao |
| |
| Affiliation: | Authors'address： Pulmonary Section 2, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | epidermal growth factor receptor non-small-cell lung cancer adjuvant therapy osimertinib |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载全文 |
|
